As inhibition of the Ras pathway has not been a promising approach in cancer therapy, a possible alternative could be to block this pathway indirectly by targeting downstream effectors of Ras, including, RalGDS, Ral, and RalBP1 37. This evidence concerns the gene RALA and cancer.